Impact of HIV co-infection on plasma level of cytokines and chemokines of pulmonary tuberculosis patients

详细信息    查看全文

• 作者：Adane Mihret (30) (31) (32)
  Markos Abebe (30)
  Yonas Bekele (30)
  Abraham Aseffa (30)
  Gerhard Walzl (32)
  Rawleigh Howe (30)
  
• 关键词：Pulmonary tuberculosis ; HIV ; Cytokines and chemokines
• 刊名：BMC Infectious Diseases
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：14
• 期：1
• 全文大小：299 KB
• 参考文献：1. Rook GA, Dheda K, Zumla A: Immune responses to tuberculosis in developing countries: implications for new vaccines. / Nat Rev Immunol 2005, 5:661-67. CrossRef
  2. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S: How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. / J Infect Dis 2005, 191:150-58. CrossRef
  3. North RJ, Jung YJ: Immunity to tuberculosis. / Annu Rev Immunol 2004, 22:599-23. CrossRef
  4. van Crevel R, Ottenhoff TH, van der Meer JW: Innate immunity to Mycobacterium tuberculosis. / Clin Microbiol Rev 2002, 15:294-09. CrossRef
  5. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. / Nature 1999, 401:708-12. CrossRef
  6. Martinez V, Carcelain G, Badell E, Jouan M, Mauger I, Sellier P, Truffot C, Bricaire F, Arend SM, Ottenhoff T, Autran B, Gicquel B: T-cell and serological responses to Erp, an exported Mycobacterium tuberculosis protein, in tuberculosis patients and healthy individuals. / BMC Infect Dis 2007, 7:83. CrossRef
  7. Demissie A, Leyten EM, Abebe M, Wassie L, Aseffa A, Abate G, Fletcher H, Owiafe P, Hill PC, Brookes R, Rook G, Zumla A, Arend SM, Klein M, Ottenhoff TH, Andersen P, Doherty TM: Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. / Clin Vaccine Immunol 2006, 13:179-86. CrossRef
  8. Toossi Z, Johnson JL, Kanost RA, Wu M, Luzze H, Peters P, Okwera A, Joloba M, Mugyenyi P, Mugerwa RD, Aung H, Ellner JJ, Hirsch CS: Increased replication of HIV-1 at sites of Mycobacterium tuberculosis infection: potential mechanisms of viral activation. / J Acquir Immune Defic Syndr 2001, 28:1-. CrossRef
  9. Goletti D, Weissman D, Jackson RW, Graham NM, Vlahov D, Klein RS, Munsiff SS, Ortona L, Cauda R, Fauci AS: Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. / J Immunol 1996, 157:1271-278.
  10. Toossi Z, Mayanja-Kizza H, Hirsch CS, Edmonds KL, Spahlinger T, Hom DL, Aung H, Mugyenyi P, Ellner JJ, Whalen CW: Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. / Clin Exp Immunol 2001, 123:233-38. CrossRef
  11. Hertoghe T, Wajja A, Ntambi L, Okwera A, Aziz MA, Hirsch C, Johnson J, Toossi Z, Mugerwa R, Mugyenyi P, Colebunders R, Ellner J, Vanham G: T cell activation, apoptosis and cytokine dysregulation in the (co) pathogenesis of HIV and pulmonary tuberculosis (TB). / Clin Exp Immunol 2000, 122:350-57. CrossRef
  12. Vanham G, Edmonds K, Qing L, Hom D, Toossi Z, Jones B, Daley CL, Huebner B, Kestens L, Gigase P, Ellner JJ: Generalized immune activation in pulmonary tuberculosis: co-activation with HIV infection. / Clin Exp Immunol 1996, 103:30-4. CrossRef
  13. Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, Navaratne L, Fisher M, Taylor GP, Miller R, Taylor CB, de Ruiter A, Pozniak AL: Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. / AIDS 2002, 16:75-3. CrossRef
  14. Kalou M, Sassan-Morokro M, Abouya L, Bile C, Maurice C, Maran M, Tossou O, Roels T, Greenberg AE, Wiktor SZ, Nkengasong JN: Changes in HIV RNA viral load, CD4+ T-cell counts, and levels of immune activation markers associated with anti-tuberculosis therapy and cotrimoxazole prophylaxis among HIV-infected tuberculosis patients in Abidjan, Cote d’Ivoire. / J Med Virol 2005, 75:202-08. CrossRef
  15. Morris L, Martin DJ, Bredell H, Nyoka SN, Sacks L, Pendle S, Page-Shipp L, Karp CL, Sterling TR, Quinn TC, Chaisson RE: Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. / J Infect Dis 2003, 187:1967-971. CrossRef
  16. Lawn SD, Shattock RJ, Acheampong JW, Lal RB, Folks TM, Griffin GE, Butera ST: Sustained plasma TNF-alpha and HIV-1 load despite resolution of other parameters of immune activation during treatment of tuberculosis in Africans. / AIDS 1999, 13:2231-237. CrossRef
  17. Mahan CS, Walusimbi M, Johnson DF, Lancioni C, Charlebois E, Baseke J, Chervenak KA, Mugerwa RD, Havlir DV, Mayanja-Kizza H, Whalen CC, Boom WH: Tuberculosis treatment in HIV infected Ugandans with CD4 counts>350 cells/mm reduces immune activation with no effect on HIV load or CD4 count. / PLoS One 2010, 5:e9138. CrossRef
  18. Mihret A, Bekele Y, Bobosha K, Kidd M, Aseffa A, Howe R, Walzl G: Plasma cytokines and chemokines differentiate between active disease and non-active tuberculosis infection. / J Infect 2012, 66:357-65. CrossRef
  19. Federal democratic republic of Ethiopia: / Guidelines for Clinical and Programmatic Management Of TB, TB/HIV and Leprosy. 5th edition. City: Ministry of health; 2013.
  20. Zhang M, Gong J, Iyer DV, Jones BE, Modlin RL, Barnes PF: T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. / J Clin Invest 1994, 94:2435-442. CrossRef
  21. Sutherland R, Yang H, Scriba TJ, Ondondo B, Robinson N, Conlon C, Suttill A, McShane H, Fidler S, McMichael A, Dorrell L: Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART. / AIDS 2006, 20:821-29. CrossRef
  22. Azzurri A, Sow OY, Amedei A, Bah B, Diallo S, Peri G, Benagiano M, D’Elios MM, Mantovani A, Del Prete G: IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. / Microbes Infect 2005, 7:1-. CrossRef
  23. Siawaya J, Beyers N, van Helden P,GW: Differential cytokine secretion and early treatment response in patients with pulmonary tuberculosis. / J Infect Dis 2009, 156:69-7.
  24. Riou C, Perez Peixoto B, Roberts L, Ronacher K, Walzl G, Manca C, Rustomjee R, Mthiyane T, Fallows D, Gray CM, Kaplan G: Effect of standard tuberculosis treatment on plasma cytokine levels in patients with active pulmonary tuberculosis. / PLoS One 2012, 7:e36886. CrossRef
  25. Bohler T, Walcher J, Holzl-Wenig G, Geiss M, Buchholz B, Linde R, Debatin KM: Early effects of antiretroviral combination therapy on activation, apoptosis and regeneration of T cells in HIV-1-infected children and adolescents. / AIDS 1999, 13:779-89. CrossRef
  26. Lancioni CL, Mahan CS, Johnson DF, Walusimbi M, Chervenak KA, Nalukwago S, Charlebois E, Havlir D, Mayanja-Kizza H, Whalen CC, Boom WH: Effects of antiretroviral therapy on immune function of HIV-infected adults with pulmonary tuberculosis and CD4+ >350 cells/mm3. / J Infect Dis 2011, 203:992-001. CrossRef
  27. Kwon DS, Angin M, Hongo T, Law KM, Johnson J, Porichis F, Hart MG, Pavlik DF, Tighe DP, Kavanagh DG, Streeck H, Addo MM, Kaufmann DE: CD4+ CD25+ regulatory T cells impair HIV-1-specific CD4 T cell responses by upregulating interleukin-10 production in monocytes. / J Virol 2012, 86:6586-594. CrossRef
  28. Bordon J, Plankey MW, Young M, Greenblatt RM, Villacres MC, French AL, Zhang J, Brock G, Appana S, Herold B, Durkin H, Golub JE, Fernandez-Botran R: Lower levels of interleukin-12 precede the development of tuberculosis among HIV-infected women. / Cytokine 2011, 56:325-31. CrossRef
  29. Jamil B, Shahid F, Hasan Z, Nasir N, Razzaki T, Dawood G, Hussain R: Interferon gamma/IL10 ratio defines the disease severity in pulmonary and extra pulmonary tuberculosis. / Tuberculosis (Edinb) 2007, 87:279-87. CrossRef
  30. The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2334/14/125/prepub
  
• 作者单位：Adane Mihret (30) (31) (32)
  Markos Abebe (30)
  Yonas Bekele (30)
  Abraham Aseffa (30)
  Gerhard Walzl (32)
  Rawleigh Howe (30)
  
  30. Armauer Hansen Research Institute, Addis Ababa, Ethiopia
  31. Department of Microbiology, Immunology and Parasitology, School of Medicine, College of Health Sciences, Addis Ababa Univrsity, Addis Ababa, Ethiopia
  32. DST/NRF Centre of Excellence for Biomedical Tuberculosis Research and MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, PO Box 19063, Francie van Zijl Drive, Tygerberg, 7505, South Africa
  
• ISSN：1471-2334

文摘

Background The immunologic environment during HIV/M. tuberculosis co-infection is characterized by cytokine and chemokine irregularities that have been shown to increase immune activation, viral replication, and T cell dysfunction. Methods We analysed ex vivo plasma samples from 17 HIV negative and 16 HIV pulmonary tuberculosis co infected cases using Luminex assay to see impact of HIV co-infection on plasma level of cytokines and chemokines of pulmonary tuberculosis patients before and after anti Tuberculosis treatment. Results The median plasma level of IFN-γ, IL-4, MCP-3, MIP-1β and IP-10 was significantly different (P-lt;-.05) before and after treatment in HIV negative TB patients but not in HIV positive TB patients. There was no significant difference between HIV positive and HIV negative TB patients (P-gt;-.05) in the plasma level of any of the cytokines or chemokines before treatment and anti TB treatment did not change the level of any of the measured cytokines in HIV positive tuberculosis patients. The ratio of IFN-γ/IL-10 and IFN-γ/IL-4 showed a significant increase after treatment in HIV negative TB cases but not in HIV positive TB cases which might indicate prolonged impairment of immune response to TB in HIV positive TB patients as compared to HIV negative tuberculosis patients. Conclusions HIV positive and HIV negative Tuberculosis patients display similar plasma cytokine and chemokine pattern. However, anti TB treatment significantly improves the Th1 cytokines and level of chemokines but does not restore the immune response in HIV positive individuals.